Kidney Disease Clinical Trial
Official title:
Evidence of Procedural Embolism Complicating Renal Artery Stenting
This study will use magnetic resonance imaging (MRI) to picture the kidney and renal
arteries (arteries that supply blood to the kidney) in patients scheduled for kidney artery
angiogram and angioplasty/stenting procedures. An angiogram is a way of taking pictures of
arteries that shows areas of narrowing caused by atherosclerosis-a buildup of plaque on the
vessel wall. Angioplasty/stent is a treatment procedure in which a balloon-tipped catheter
is inserted in the artery and advanced to the area of blockage to open the vessel,
increasing blood flow to the kidney. A permanent metal tube (stent) may or may not be put in
place to maintain the opening. During either of these invasive procedures, small pieces of
plaque can break off and travel in the blood to lodge elsewhere in the body. This is called
embolization. Lodged in the kidney, the embolus can impair kidney function. Currently, these
emboli cannot be detected. A new way of visualizing the kidneys that allows detection of
emboli may reveal whether material has moved to the kidneys and predict if there will be any
kidney damage.
Patients 21 years of age and older with suspected kidney artery disease scheduled for
invasive angiographic evaluation in NIH protocol 95-H-0047 may be eligible for this study.
Participants will be assigned to one of two study groups, based on the angiogram findings
and the decision to have the angioplasty/stent procedure. Participants in both groups will
have baseline MRI scans up to 2 weeks before the invasive procedure (angiogram with or
without angioplasty/stent) and again within a day after the procedure. Patients who undergo
angioplasty/stent will have another MRI study within about a month following the procedure.
MRI uses a magnetic field and radio waves to produce images of body tissues. The patient
lies on a table that slides into a large hollow tube (the scanner). During part of the scan,
a material called gadolinium contrast may be injected into a vein. This substance brightens
the images to better show the kidneys, their blood vessels and blood flow. The procedure
lasts from about 1 to 2 hours. During the MRI, the heart is monitored with an
electrocardiogram (EKG) and breathing is monitored with a flexible belt. Blood pressure is
measured intermittently. The patient can communicate with a staff member at all times.
Blood samples will be drawn from an arm vein at the initial clinic visit, within a day after
the procedure and about 1 week after the procedure. For patients who had the
angioplasty/stent procedure, a third blood sample will be taken within another 6 six weeks.
The blood samples will be used to check for changes in kidney function.
Atherosclerotic renal artery stenosis (ARAS) is common and is associated with uncontrolled
hypertension and renal excretory dysfunction. Percutaneous stenting of ARAS effectively
relieves arterial obstruction, but approximately one-quarter of patients derives no apparent
clinical benefit or actually suffers deterioration in renal excretory function. There are
reasons to suspect that percutaneous renal intervention is associated with embolization of
aorto-ostial atheromatous debris, which may lead to adverse clinical outcomes. There are no
known clinical, imaging, or biochemical markers of renal embolism or ischemic necrosis.
Investigational or clinical detection of such events might guide future modification of
mechanical interventional technique, for example, with the introduction of procedural
embolic protection devices.
This pilot study of patients undergoing percutaneous transluminal renal artery stenting
(PTRAS) will attempt to image embolization using magnetic resonance imaging (MRI).
;
Endpoint Classification: Safety Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02369354 -
Transplant Social Worker Support for Live Kidney Donation in African Americans
|
N/A | |
Not yet recruiting |
NCT02225782 -
Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function
|
Phase 4 | |
Completed |
NCT00499187 -
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
|
Phase 4 | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Completed |
NCT00183248 -
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00001835 -
Oxaliplatin in Cancer Patients With Impaired Kidney Function
|
Phase 1 | |
Completed |
NCT01331941 -
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
|
Phase 1 | |
Terminated |
NCT00436748 -
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT01467466 -
Prevention of Serious Adverse Events Following Angiography
|
Phase 3 | |
Completed |
NCT01235936 -
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
|
Phase 2 | |
Completed |
NCT01974999 -
A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
|
||
Completed |
NCT01947829 -
Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)
|
N/A | |
Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
Active, not recruiting |
NCT01228903 -
Uric Acid and the Endothelium is CKD
|
N/A | |
Completed |
NCT00734357 -
Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients
|
N/A | |
Completed |
NCT00781417 -
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease
|
N/A | |
Completed |
NCT00094484 -
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
|
Phase 3 | |
Completed |
NCT00096915 -
Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
|
Phase 3 | |
Completed |
NCT00185159 -
Olmesartan Medoxomil in Diabetes Mellitus
|
Phase 3 |